FENC — Fennec Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $221.33m
- $184.54m
- $44.64m
Annual income statement for Fennec Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 1.53 | 21.3 | 47.5 | 44.6 |
| Cost of Revenue | |||||
| Gross Profit | — | 1.45 | 20 | 44.4 | 40.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 17.2 | 24.1 | 34 | 45 | 52.9 |
| Operating Profit | -17.2 | -22.6 | -12.8 | 2.57 | -8.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.3 | -23.7 | -16 | -0.071 | -9.63 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.3 | -23.7 | -16 | -0.436 | -9.74 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.3 | -23.7 | -16 | -0.436 | -9.74 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -17.3 | -23.7 | -16 | -0.436 | -9.74 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.667 | -0.903 | -0.604 | -0.016 | -0.295 |